Clinical trial
A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast…
NCT00109265 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00109265 |
|---|---|
| Title | A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy |
| Official title | A Phase II, Multicenter, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of OSI-774 in Patients With Advanced or Metastatic Breast Cancer and Disease Progression During or Following Chemotherapy |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib HCl (OSI-774) |
| Start date | May 1, 2001 |
| Completion | Oct 1, 2002 |
| First posted | Apr 26, 2005 |
| Last update posted | Jul 2, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: